| (Values in U.S. Thousands) | Aug, 2024 | Aug, 2023 | May, 2021 | May, 2020 | May, 2019 |
| Sales | 2,739 | 1,152 | 3,722 | 509 | 171 |
| Sales Growth | +137.76% | -69.05% | +631.24% | +197.66% | -28.75% |
| Net Income | -3,628 | 4,104 | -4,628 | -8,459 | -8,012 |
| Net Income Growth | -188.40% | +188.68% | +45.29% | -5.58% | -26.33% |
Oncimmune Holdings Plc (ONC.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Oncimmune Holdings PLC is engaged in diagnosing cancer. It is involved in the development, manufacturing, and commercialization of personalized immunodiagnostics for the screening, detection, and care of cancer. The company's operating segment is ImmunoINSIGHTS.
Fiscal Year End Date: 08/31